NCT06492005View on ClinicalTrials.gov

A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

July 26, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions
Triple-Negative Breast Cancer
Interventions
DRUG

9MW2821

Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol

DRUG

PD-1 inhibitior

Subjects will receive intravenous (IV) infusion of PD-1 inhibitor as per protocol

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY